SVRA - Savara Inc logo

Savara Inc

SVRA

Savara Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. Its lead product, molgramostim, is an inhaled therapy in Phase 3 for autoimmune pulmonary alveolar proteinosis.

⚕️ Healthcare NASDAQ Listed 2017 $ USD
$1,000 invested 20 years ago →$1today

Score Overview

1 Year
Score—
Net Growth-17.23%
Net TrendShrank
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
5 Years
Score1.1
Net Growth-223.87%
Net Trend20%
Net Income Consistency—
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency—
All Time
Score—
Net Growth-367.53%
Net Trend33%
Net Income Consistency
Rev Growth—
Rev Trend11%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Savara Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. SVRA does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 4.54—
1 Year2025-10-22
$ 4.1110.46%
5 Years2021-10-22
$ 1.21275.21%
10 Years2016-10-21
$ 6.02-24.58%
20 Years2006-10-20
$ 4.62K-99.90%
All Time2017-06-01
$ 5.16-12.02%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 139M$ 173M
2025$ 0.00-$ 118M$ 235M
2024$ 0.00-$ 95M$ 196M
2023$ 0.00-$ 54M$ 162M
2022$ 0.00-$ 38M$ 125M
2021$ 1K-$ 43M$ 161M
2020$ 257K-$ 49M$ 82M
2019$ 0.00-$ 78M$ 121M
2018$ 0.00-$ 61M$ 110M
IPO2017$ 0.00-$ 29M$ 94M
SVRA - Savara Inc logo

Savara Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 257K to $ 0.00 and net income went from -$ 49M to -$ 118M. Revenue increased in 0 of those 5 years; net income in 1.

Savara Inc currently holds a 5-year HDB Score of 1.1 out of 10. How the HDB Score is calculated.

Membership

Explore SVRA with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies